comparemela.com

Westlake Village-based Arcutis Biotherapeutics announced that its main treatment option, Zoryve, received approval from the U.S. Drug and Food Administration for treating a skin condition called seborrheic dermatitis, the company announced on Dec. 15 It is the second FDA approval received by Arcutis’ Zoryve, being approved to be used in individuals nine years of age

Related Keywords

Seamus Fernandez ,Arcutis Biotherapeutics ,Frank Watanabe ,Arcuti Zoryve ,Reuters ,Food Administration ,Jorge Mercado Friday ,Health Care Amp Life Science ,Latest News ,Subscriber Content ,Top Stories ,Top Story ,Tri County Economy ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.